Evidence map›Paper›PMID 31583301›Full record

ArticleJournal of the anus, rectum and colon2017

A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer.

Masataka Ikeda, Mitsugu Sekimoto, Yosuke Fukunaga, Koji Konishi, Yushi Fujiwara, Tsunekazu Mizushima, Ichiro Takemasa, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the anus, rectum and colon, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Masataka IkedaDepartment of Surgery, Osaka National Hospital, Osaka, Japan.
Mitsugu SekimotoDepartment of Surgery, Osaka National Hospital, Osaka, Japan.
Yosuke FukunagaDepartment of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan.
Koji KonishiDepartment of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Yushi FujiwaraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tsunekazu MizushimaDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Ichiro TakemasaDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Hirofumi YamamotoDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Yuichiro DokiDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Masaki MoriDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Osaka University · JPOsaka National Hospital · JPOsaka City University · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPThe Cancer Institute Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this phase I study is to identify the maximum tolerated dose (MTD) and recommended dose (RD) of CPT-11 in combination with UFT/LV and radiation in patients with locally recurrent rectal cancer.

methodsPatients with histologically proven rectal cancer with local recurrence were eligible for this study. Escalating doses of CPT-11 (30-60 mg/m

resultsWe recruited 27 patients, and the MTD of CPT-11 was 60 mg/m

conclusionsThe combined chemoradiotherapy with oral UFT/LV plus CPT-11 is feasible and promising. The recommended dose for further phase II trials is determined to be 50 mg/m

Indexed as

chemoradiationCPT-11locally recurrent rectal cancerphase I studyUFT/LV

Identifiers

PMID31583301
PMCPMC6768668
OpenAlexW2608931283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.